112 related articles for article (PubMed ID: 18094659)
1. Outpatient chemotherapy plus radiotherapy in sarcomas: improving cancer control with radiosensitizing agents.
Anderson P; Aguilera D; Pearson M; Woo S
Cancer Control; 2008 Jan; 15(1):38-46. PubMed ID: 18094659
[TBL] [Abstract][Full Text] [Related]
2. Novel therapeutic approaches in pediatric and young adult sarcomas.
Anderson PM; Pearson M
Curr Oncol Rep; 2006 Jul; 8(4):310-5. PubMed ID: 17254532
[TBL] [Abstract][Full Text] [Related]
3. Ifosfamide-containing chemotherapy in Ewing's sarcoma: The Second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's Tumor Study.
Craft A; Cotterill S; Malcolm A; Spooner D; Grimer R; Souhami R; Imeson J; Lewis I
J Clin Oncol; 1998 Nov; 16(11):3628-33. PubMed ID: 9817284
[TBL] [Abstract][Full Text] [Related]
4. [Soft tissue sarcoma: postoperative chemotherapy].
Goto T; Kosaku H; Kobayashi H; Hozumi T; Kondo T
Gan To Kagaku Ryoho; 2004 Sep; 31(9):1324-30. PubMed ID: 15446551
[TBL] [Abstract][Full Text] [Related]
5. Ambulatory administration of 5-day infusion ifosfamide+mesna: a pilot study in sarcoma patients.
Coriat R; Mir O; Camps S; Ropert S; Billemont B; Leconte M; Larousserie F; Anract P; Alexandre J; Goldwasser F
Cancer Chemother Pharmacol; 2010 Feb; 65(3):491-5. PubMed ID: 19588140
[TBL] [Abstract][Full Text] [Related]
6. [Preoperative adjuvant therapy for primary malignant bone tumors].
Goto T; Okuma T; Nakada I; Hozumi T; Kondo T
Gan To Kagaku Ryoho; 2007 Nov; 34(11):1750-4. PubMed ID: 18030009
[TBL] [Abstract][Full Text] [Related]
7. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence.
Patel SR; Vadhan-Raj S; Papadopolous N; Plager C; Burgess MA; Hays C; Benjamin RS
J Clin Oncol; 1997 Jun; 15(6):2378-84. PubMed ID: 9196153
[TBL] [Abstract][Full Text] [Related]
8. Ifosfamide plus etoposide in newly diagnosed Ewing's sarcoma of bone.
Meyer WH; Kun L; Marina N; Roberson P; Parham D; Rao B; Fletcher B; Pratt CB
J Clin Oncol; 1992 Nov; 10(11):1737-42. PubMed ID: 1403056
[TBL] [Abstract][Full Text] [Related]
9. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas.
Antman K; Crowley J; Balcerzak SP; Rivkin SE; Weiss GR; Elias A; Natale RB; Cooper RM; Barlogie B; Trump DL
J Clin Oncol; 1993 Jul; 11(7):1276-85. PubMed ID: 8315425
[TBL] [Abstract][Full Text] [Related]
10. Feasibility of Preoperative Chemotherapy With or Without Radiation Therapy in Localized Soft Tissue Sarcomas of Limbs and Superficial Trunk in the Italian Sarcoma Group/Grupo Español de Investigación en Sarcomas Randomized Clinical Trial: Three Versus Five Cycles of Full-Dose Epirubicin Plus Ifosfamide.
Palassini E; Ferrari S; Verderio P; De Paoli A; Martin Broto J; Quagliuolo V; Comandone A; Sangalli C; Palmerini E; Lopez-Pousa A; De Sanctis R; Bottelli S; Libertini M; Picci P; Casali PG; Gronchi A
J Clin Oncol; 2015 Nov; 33(31):3628-34. PubMed ID: 26351345
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of ifosfamide and cisplatin in the treatment of metastatic sarcomas: a Southwest Oncology Group study.
Budd GT; Metch B; Weiss SA; Weick JK; Fabian C; Stephens RL; Balcerzak SP
Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S213-6. PubMed ID: 8453701
[TBL] [Abstract][Full Text] [Related]
12. [Indication of chemotherapy according to histological type of musculoskeletal sarcomas].
Goto T; Okuma T; Ogura K; Imanishi J; Hozumi T; Kondo T
Gan To Kagaku Ryoho; 2009 Feb; 36(2):199-203. PubMed ID: 19223736
[TBL] [Abstract][Full Text] [Related]
13. Single-agent ifosfamide studies in sarcomas of soft tissue and bone: the M.D. Anderson experience.
Benjamin RS; Legha SS; Patel SR; Nicaise C
Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S174-9. PubMed ID: 8453693
[TBL] [Abstract][Full Text] [Related]
14. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy.
Elias A; Ryan L; Sulkes A; Collins J; Aisner J; Antman KH
J Clin Oncol; 1989 Sep; 7(9):1208-16. PubMed ID: 2504890
[TBL] [Abstract][Full Text] [Related]
15. Concomitant administration of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for high-risk sarcomas: the St. Jude Children's Research Hospital experience.
Navid F; Santana VM; Billups CA; Merchant TE; Furman WL; Spunt SL; Cain AM; Rao BN; Hale GA; Pappo AS
Cancer; 2006 Apr; 106(8):1846-56. PubMed ID: 16541446
[TBL] [Abstract][Full Text] [Related]
16. [The effects of high-dose ifosfamide in the treatment of bone and soft tissue sarcomas].
Ishii T; Tatezaki S; Satoh T; Yonemoto T; Umeda T; Kitoh M
Gan To Kagaku Ryoho; 1997 Nov; 24(14):2123-30. PubMed ID: 9388523
[TBL] [Abstract][Full Text] [Related]
17. [Toxic effects of ifosfamide in the treatment of bone and soft tissue sarcomas].
Ishii T; Umeda T; Kitoh M; Tatezaki S; Satoh T
Gan To Kagaku Ryoho; 1993 Mar; 20(4):509-14. PubMed ID: 8452388
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine radiosensitization after high-dose samarium for osteoblastic osteosarcoma.
Anderson PM; Wiseman GA; Erlandson L; Rodriguez V; Trotz B; Dubansky SA; Albritton K
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6895-900. PubMed ID: 16203780
[TBL] [Abstract][Full Text] [Related]
19. Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults.
Miser JS; Kinsella TJ; Triche TJ; Tsokos M; Jarosinski P; Forquer R; Wesley R; Magrath I
J Clin Oncol; 1987 Aug; 5(8):1191-8. PubMed ID: 3114435
[TBL] [Abstract][Full Text] [Related]
20. Phase 1 European Organisation for Research and Treatment of Cancer study determining safety of pegylated liposomal doxorubicin (Caelyx) in combination with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas.
Nielsen OS; Reichardt P; Christensen TB; Pink D; Daugaard S; Hermans C; Marreaud S; van Glabbeke M; Blay J; Judson I
Eur J Cancer; 2006 Sep; 42(14):2303-9. PubMed ID: 16891112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
